CHINA – Eluminex Biosciences, a Suzhou, China and San Francisco, CA-based biotechnology company focusing on ophthalmic diseases and recombinant human collagen technology, raised $40+ M in Series B funding.
The round was led by Cenova Capital with participation from Guangzhou Yuexiu Industrial Investment Fund Management, 3E Bioventures Capital, Oriza Holdings, and Series A investors.The company intends to use the funds to expand its development efforts. Founded in February 2020 and led by Dr. Jinzhong Zhang, Founder, Chairman and CEO, Eluminex is a clinical-stage biotechnology company dedicated to the research and development of global innovative therapeutics with a focus on ophthalmology and recombinant human collagen technology. Eluminex’ pipeline programs include novel multi-targeted antibody molecules for vision-threatening retinal diseases, an oral small molecule for rare inherited pediatric retinal dystrophies, and the clinical development and manufacturing of recombinant human collagen-based products with the potential to be world’s first biosynthetic cornea for the treatment of corneal stromal blinding diseases. The company is currently building a GMP facility in BioBAY of Suzhou Industrial Park for the manufacturing of the recombinant human collagen biosynthetic cornea and other collagen-based products and is expected to operate in mid-2023.Eluminex also has a clinical and registration center located in South San Francisco, California.28/02/2023
